OCULAR THERAPEUTIX, INC Sales Revenue, Goods, Net (Deprecated 2018-01-31)
OCULAR THERAPEUTIX, INC (OCUL) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $487.00 thousand for the 3-month period ending 2017-12-31, per its 10-K filed 2018-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-08
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $487.00K, a 4.70% decline year-over-year.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $523.00K, a 9.64% increase year-over-year.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $438.00K, a 0.68% decline year-over-year.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $475.00K, a 14.18% increase year-over-year.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $1.92M, a 4.23% increase from fiscal 2016.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $1.84M, a 36.26% increase from fiscal 2015.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $1.35M, a 194.35% increase from fiscal 2014.
- OCULAR THERAPEUTIX, INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $460.00K.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $487.00K 10-K · filed 2018-03-08 | $1.01M derived: sum of 2 quarters · filed 2018-03-08 | $1.45M derived: sum of 3 quarters · filed 2018-03-08 | $1.92M 10-K · filed 2018-03-08 |
| 2017-09-30 | $523.00K 10-K · filed 2018-03-08 | $961.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.44M 10-Q · filed 2017-11-07 | $1.95M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-06-30 | $438.00K 10-K · filed 2018-03-08 | $913.00K 10-Q · filed 2017-08-08 | $1.42M derived: sum of 3 quarters · filed 2018-03-08 | $1.90M derived: sum of 4 quarters · filed 2018-03-08 |
| 2017-03-31 | $475.00K 10-K · filed 2018-03-08 | $986.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.46M derived: sum of 3 quarters · filed 2018-03-08 | $1.90M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-12-31 | $511.00K 10-K · filed 2018-03-08 | $988.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.43M derived: sum of 3 quarters · filed 2018-03-08 | $1.84M 10-K · filed 2018-03-08 |
| 2016-09-30 | $477.00K 10-K · filed 2018-03-08 | $918.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.33M 10-Q · filed 2017-11-07 | $1.73M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $441.00K 10-Q · filed 2016-08-09 | $857.00K 10-Q · filed 2017-08-08 | $1.25M derived: sum of 3 quarters · filed 2018-03-08 | $1.64M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $416.00K 10-K · filed 2018-03-08 | $810.00K derived: sum of 2 quarters · filed 2018-03-08 | $1.20M derived: sum of 3 quarters · filed 2018-03-08 | $1.53M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $394.00K 10-K · filed 2017-03-10 | $782.00K derived: sum of 2 quarters · filed 2017-03-10 | $1.12M derived: sum of 3 quarters · filed 2017-03-10 | $1.35M 10-K · filed 2018-03-08 |
| 2015-09-30 | $388.00K 10-K · filed 2017-03-10 | $722.00K derived: sum of 2 quarters · filed 2017-03-10 | $960.00K 10-Q · filed 2016-11-09 | $1.15M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | $334.00K 10-K · filed 2017-03-10 | $572.00K 10-Q · filed 2016-08-09 | $765.00K derived: sum of 3 quarters · filed 2017-03-10 | $908.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $238.00K 10-K · filed 2017-03-10 | $431.00K derived: sum of 2 quarters · filed 2017-03-10 | $574.00K derived: sum of 3 quarters · filed 2017-03-10 | $671.00K derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | $193.00K 10-K · filed 2016-03-10 | $336.00K derived: sum of 2 quarters · filed 2016-03-10 | $433.00K derived: sum of 3 quarters · filed 2016-03-10 | $460.00K 10-K · filed 2017-03-10 |
| 2014-09-30 | $143.00K 10-K · filed 2016-03-10 | $240.00K derived: sum of 2 quarters · filed 2016-03-10 | $267.00K 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $97.00K 10-K · filed 2016-03-10 | $124.00K 10-Q · filed 2015-08-10 | ||
| 2014-03-31 | $27.00K 10-K · filed 2016-03-10 | |||
| 2012-12-31 | $10.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |